/**
 * Long-form SSR sections for GSC P0 specialty market demand pages (≥2k word target).
 */

type LongFormSection = { heading: string; paragraphs: string[] };

export const SPECIALTY_DEMAND_LONG_FORM: Record<string, LongFormSection[]> = {
  'japan-medical-disposables-market': [
    {
      heading: 'Regulatory and QI context for hospital disposables in Japan',
      paragraphs: [
        'Hospital disposables in Japan sit inside MHLW infection-prevention guidance, accreditation cycles, and internal quality indicators — not only procurement score sheets. Infection-control committees translate national guidance into ward-level standards for drapes, antiseptics, PPE, and procedure kits. When accreditation visits approach, committees often tighten SKU lists and documentation requirements faster than tender calendars refresh. BioNixus captures those committee rhythms so manufacturers do not mistime a launch for the month before a hospital freezes category changes.',
        'Nursing unions and ward managers influence disposables through usability reviews that never appear in public tender documents. A product that saves a few yen per unit but adds steps to bedside workflow is frequently removed after a single quarterly review even if procurement signed a multi-year contract. Primary research therefore pairs procurement interviews with ward and infection-control depth — averaging them produces misleading “price wins” narratives.',
        'For foreign manufacturers, documentation quality and Japanese-language IFU support often matter as much as clinical claims. Biomedical and materials-management teams track fill rates, back-order frequency, and substitution approvals. Shortage history on a competitor can open a window; shortage history on your brand can lock you out of dual-source consideration for years.',
      ],
    },
    {
      heading: 'Account strategy: public clusters, privates, and export-linked buyers',
      paragraphs: [
        'Public university hospitals, regional medical centres, and private groups follow different tender calendars and nursing cultures. A disposable strategy that works in Tokyo academic centres may fail in regional hospitals where group purchasing terms are stricter but nursing veto power is stronger. BioNixus maps account tiers and links them to tender windows rather than publishing a single national “market size”.',
        'Manufacturers serving both Japan domestic wards and GCC tenders should separate evidence packs. Gulf buyers may ask about origin of manufacture and sterilisation standards; Japanese wards ask about kit design and training burden. When the same SKU serves both, research modules should still interview the relevant stakeholder set for each decision — not reuse one average message.',
        'Service expectations after award include training refreshers, emergency shipment clauses, and kanban restocking reliability. Distributors remain commercially important; BioNixus includes them when they own service SLAs that nursing teams actually experience.',
      ],
    },
    {
      heading: 'Research design BioNixus uses for Japan disposables programmes',
      paragraphs: [
        'Feasibility confirms category scope, account list, and stakeholder mix before protocols lock. Qualitative depth typically runs twelve to eighteen interviews per cell (infection control, nursing, procurement) until thematic saturation on switching barriers. Optional quant attaches when a tender or standardisation vote is dated and incidence supports cuts by account type.',
        'Deliverables include an executive decision memo, objection library, tender calendar for named accounts, and a ninety-day action plan with owners. For multinational teams, we can add a GCC linkage appendix when origin-of-manufacture evidence must travel into NUPCO or MOHAP dossiers.',
        'All hospital stakeholder research follows documented consent, de-identified reporting, and role verification suitable for internal audit and medical affairs review — consistent with BioNixus healthcare fieldwork standards across forty-eight countries.',
      ],
    },
  ],
  'japan-neurology-devices-market': [
    {
      heading: 'PMDA, NHI, and hospital economics for neurology devices',
      paragraphs: [
        'Neurology devices in Japan clear PMDA but earn utilization through NHI reimbursement categories, DPC economics, and stroke-network protocols. Capital neuro systems and high-cost disposables face different committee clocks; mixing them in one “neurology survey” produces unactionable averages. BioNixus separates capital planning interviews from interventional disposable panels.',
        'Device lag reduction reforms raised sponsor expectations for near-concurrent launch planning with US or EU approvals. Hospitals still gate adoption on proctoring capacity, complication management training, and biomedical maintenance bandwidth. KOL endorsement without proctor availability rarely scales beyond a single centre.',
        'Domestic OEMs set service and training baselines foreign entrants must match or differentiate clearly. Primary research documents those baselines as objection themes rather than syndicated share estimates.',
      ],
    },
    {
      heading: 'Stroke networks and neurosurgery account mapping',
      paragraphs: [
        'Designated stroke centres concentrate interventional volume and set regional protocol templates. Mapping which centres anchor each network tells commercial teams where proctoring investment returns most. BioNixus stroke-network modules identify protocol owners, not only famous KOL names.',
        'Neurosurgery capital competes with other service lines under unified hospital budgets. Research with hospital finance and department heads clarifies how neuro robotics, navigation, or monitoring platforms are prioritized against orthopaedic or cardiac capital in the same fiscal window.',
        'Distributor technical specialists and proctors are part of the adoption system. Interviewing them reveals training bottlenecks that physician-only panels miss.',
      ],
    },
    {
      heading: 'Programme outputs for neurology device clients',
      paragraphs: [
        'Typical deliverables include account prioritisation, KOL and proctor map, competitive objection library, and message tests where medical affairs needs defensible claims. Optional quant surveys estimate adoption intent or share-of-protocol metrics when sample frames support cuts by region and centre type.',
        'For APAC headquarters using Japan as reference, we flag which evidence travels to ASEAN tenders versus which remains Japan-specific — reducing reused slide decks that fail local committee scrutiny.',
        'Programmes anchor on one commercial decision: launch sequencing, competitive defence, or training investment — documented in the charter before field begins.',
      ],
    },
  ],
  'singapore-ivd-market-access': [
    {
      heading: 'HSA registration versus cluster lab adoption',
      paragraphs: [
        'HSA IVD listing establishes regulatory eligibility; SingHealth, NUHS, and NHG cluster laboratories decide whether an assay runs at scale. Method validation, QC alignment, and reagent rental economics sit with lab directors and pathologists who may never appear on a sponsor’s CRM account list. BioNixus recruits those buyers deliberately.',
        'Precision oncology and high-complexity panels raise evidence expectations beyond registration dossiers. Companion diagnostics need ordering-specialist pull and lab validation simultaneously — failure on either lane leaves registered-but-unused SKUs.',
        'Point-of-care expansion creates parallel buyer sets in wards and clinics with different governance than central labs. Access research must declare which POCT pathway is in scope before interviewing clinicians.',
      ],
    },
    {
      heading: 'Platform lock-in and competitive switching costs',
      paragraphs: [
        'Analyser platforms and long reagent contracts create switching costs that outlast individual assay registrations. Installed-base research documents platform share, contract end dates, and service satisfaction — inputs to realistic share forecasts.',
        'Cluster standardisation means winning one lab menu can bind sister hospitals; challengers must plan multi-year evidence and service strategies, not single-assay discounts.',
        'APAC regional teams often pilot in Singapore before Malaysia or Indonesia; BioNixus notes where Singapore lab credibility transfers to ASEAN tenders and where separate validation is still required.',
      ],
    },
    {
      heading: 'Singapore IVD access research deliverables',
      paragraphs: [
        'Readouts separate registered vs running assays, cluster-by-cluster adoption barriers, and procurement scoring themes. Message testing modules run only after lab-leadership barriers are documented — otherwise clinician copy tests optimise the wrong gate.',
        'Deliverables align to medical affairs, market access, and commercial roles with consistent underlying evidence tables. dateModified on page schema reflects content refreshes tied to cluster policy changes when sponsors republish.',
        'Proposal turnaround targets forty-eight hours from objective alignment for scoped Singapore IVD access modules.',
      ],
    },
  ],
  'mek-inhibitors-market': [
    {
      heading: 'Biomarker pathways and sequencing reality',
      paragraphs: [
        'MEK utilisation requires reflex testing rules, molecular pathology capacity, and acceptable turnaround times. When labs batch send-outs or limit panel breadth, eligible patients never reach the prescribing decision — a volume cap unrelated to price. BioNixus pathology modules document those caps by institution.',
        'Line-of-therapy sequencing interacts with combination regimens: partner-drug access, prior therapy rules, and payer step edits can block MEK initiation even with a cleared label. Oncologist interviews map sequencing choices indication by indication rather than as a class average.',
        'Medical affairs teams need objection libraries tied to testing and sequencing — not only efficacy slides. Primary research supplies those libraries from verified prescribers and pathologists.',
      ],
    },
    {
      heading: 'Payer, HTA, and hospital formulary gates',
      paragraphs: [
        'Funding pathways differ for inpatient versus oral outpatient MEK combinations. Hospital P&T, national payer, and tender channels may disagree on evidence sufficiency. Research identifies which gate is binding in each target market cell on the launch plan.',
        'RWE requests at formulary appear more often for high-cost targeted therapy. BioNixus can scope RWE modules adjacent to qual when committees ask for local persistence or resource-use data — without conflating them into one undifferentiated “MEK survey”.',
        'GCC modules add NUPCO framework and hospital pharmacy substitution themes when Gulf listing is on the path — listing without pull-through remains a common failure mode.',
      ],
    },
    {
      heading: 'MEK access programme design',
      paragraphs: [
        'Charter one decision: sequencing defence, testing enablement, tender pull-through, or message optimisation. Feasibility validates oncologist and pathologist incidence before quant scales.',
        'Deliverables include executive synthesis, stakeholder-specific readouts, and optional message test report with verbatim objection themes suitable for MLR review.',
        'Cross-link MEK modules with febrile neutropenia or supportive-care research only when regimen adjacency is explicitly on the decision path — avoiding generic oncology blur.',
      ],
    },
  ],
  'febrile-neutropenia-market': [
    {
      heading: 'Prophylaxis protocols and G-CSF choice',
      paragraphs: [
        'Primary versus secondary prophylaxis rules set the eligible pool for G-CSF brands and biosimilars. Protocol updates after society guideline changes can shift volumes faster than tender awards. BioNixus maps protocol owners and pharmacy substitution rules together.',
        'Pegfilgrastim versus filgrastim formats, device-assisted administration, and day-clinic scheduling interact with nursing preference and pharmacy inventory policies. Treating “G-CSF” as one SKU category hides switching dynamics that drive P&L.',
        'Inpatient febrile neutropenia treatment pathways involve infectious disease and emergency stakeholders adjacent to prophylaxis decisions — relevant when brands message admission reduction.',
      ],
    },
    {
      heading: 'Biosimilars, tenders, and shortage behaviour',
      paragraphs: [
        'Hospital pharmacies accelerate biosimilar switches after tender changes when confidence and interchange policies allow. Oncologist trust still matters for primary prophylaxis continuation — pharmacy-led substitution without clinical sign-off can revert quickly.',
        'Shortage history shapes dual-source and buffer-stock policies that persist after supply normalises. Primary research captures those policies as structural share barriers.',
        'GCC framework awards for supportive-care injectables require pull-through modules — pharmacy and ward adoption — not only listing celebrations.',
      ],
    },
    {
      heading: 'FN and supportive-care research outputs',
      paragraphs: [
        'Deliverables highlight protocol stickiness, tender calendars, switching barriers, and message themes for medical affairs. Quant modules attach when a dated tender or P&T vote is the stated decision.',
        'Programs respect separation of prophylaxis, treatment, and tender economics in reporting even when one sponsor team funds all modules — preventing mixed readouts that committees cannot act on.',
        'Link to oncology hub and GCC injectables pages for internal navigation; external SEO benefits from substantive SSR on febrile neutropenia and G-CSF intent queries.',
      ],
    },
  ],
  'italy-portable-diagnostic-devices-market': [
    {
      heading: 'POCT governance and regional variation in Italy',
      paragraphs: [
        'Hospital POCT programmes require method validation, QC, and lab director sign-off before wards scale usage. ED and ICU may pilot devices that central labs slow-roll — research must capture both sides of that tension.',
        'Regional ASL and hospital group tenders embed connectivity, service, and IVDR documentation requirements that differ from north to south. National market slides understate tender friction BioNixus validates regionally.',
        'Community and ambulatory pathways expand cardiometabolic and respiratory POCT outside acute settings — a different buyer set from hospital lab governance.',
      ],
    },
    {
      heading: 'Economics: reagent rental, throughput, and LIS integration',
      paragraphs: [
        'Reagent rental and throughput assumptions drive renewals more than capital list price. Lab directors model total cost per test with downtime and QC burden included.',
        'LIS/HIS integration is table stakes; cybersecurity review cycles lengthen for connected POCT fleets. IT stakeholders belong in access research early, not as an afterthought.',
        'Switching costs from incumbent benchtop or central-lab workflows include retraining, validation rework, and contractual exit penalties — documented in installed-base modules.',
      ],
    },
    {
      heading: 'Italy portable diagnostics programme outputs',
      paragraphs: [
        'Deliverables include pathway-specific adoption maps, regional tender themes, lab validation barrier summary, and account prioritisation for commercial teams.',
        'Cross-link portable diagnostics with Italy connectivity research when devices require integration evidence — but keep POCT governance modules distinct from hospital IT architecture studies.',
        'Feasibility confirms lab and clinical role access before scaling interviews across regions.',
      ],
    },
  ],
  'italy-medical-device-connectivity-market': [
    {
      heading: 'Hospital IT coalitions for connected devices',
      paragraphs: [
        'CIO offices set interface standards; cybersecurity teams gate risk acceptance; clinical engineering owns uptime and patching. Clinical department sponsors provide budget pull but rarely override IT veto on connected fleets.',
        'Microservices and modular architecture preferences vary by hospital IT maturity — legacy HIS stacks favour proven interfaces over vendor roadmaps. BioNixus tests architecture claims with architecture owners, not sales engineers alone.',
        'GDPR and hospital privacy offices review data flows from devices to EMR and cloud analytics. Evidence packs must address retention, encryption, and breach processes to survive diligence.',
      ],
    },
    {
      heading: 'Tenders, MDR PMS, and regional digital health programmes',
      paragraphs: [
        'Regional tenders increasingly specify interoperability clauses, uptime SLAs, and cybersecurity artefacts. Scraping tender text alone misses how evaluators weight those clauses — buyer interviews clarify scoring.',
        'MDR post-market surveillance obligations push hospitals to capture device data more systematically — a demand driver for connectivity but also a compliance burden that slows go-live.',
        'National and regional digital health investments raise expectations but do not automatically fund device connectivity; sponsorship must be mapped account by account.',
      ],
    },
    {
      heading: 'Connectivity research deliverables',
      paragraphs: [
        'Outputs include coalition maps, IT objection libraries, interoperability evidence checklists, and regional tender language summaries actionable for product and regulatory teams.',
        'Clinical engineering and CIO qual precedes clinician message tests when IT is the binding gate — reversing that order wastes field budget.',
        'Compare Italy modules with Japan access-automation research only when multinational clients harmonise instruments — not by default.',
      ],
    },
  ],
  'gcc-medication-management-market': [
    {
      heading: 'Inpatient automation versus ambulatory e-prescribing',
      paragraphs: [
        'Automated dispensing cabinets, unit-dose workflows, and compounding automation compete for capital budgets with HIS upgrades and imaging investments. Chief pharmacists co-sponsor with quality leaders when error-reduction proof is credible; CIOs co-sponsor when integration risk is low.',
        'Closed-loop e-prescribing and administration require clinician workflow buy-in — nursing and physician resistance can stall projects after pharmacy and IT approval. Research captures workflow friction explicitly.',
        'Wasfaty and Saudi ambulatory programmes link outpatient prescribing to retail pharmacy fulfilment — a distinct medication-management lane from inpatient ADC projects.',
      ],
    },
    {
      heading: 'Adherence, chronic care, and payer-sponsored programmes',
      paragraphs: [
        'Adherence platforms and patient-support programmes often fund from payer or employer budgets rather than hospital capex. Evidence expectations differ — ROI on avoided admissions versus member retention.',
        'Chronic disease burden in the Gulf raises interest in refill reminders, coaching, and digital therapeutics adjacency. Sponsorship varies by country insurance structure and employer density.',
        'High-cost specialty drugs increase need for inventory visibility and cold-chain tracking — tender criteria BioNixus maps in pharmacy and quality interviews.',
      ],
    },
    {
      heading: 'GCC medication management fieldwork standards',
      paragraphs: [
        'Arabic–English instruments and moderation are standard; hospital access is feasibility-gated before multi-country roll-ups. Saudi mega-projects and UAE private groups often lead timelines — harmonised surveys still include country qual cells.',
        'Deliverables separate automation, e-Rx, and adherence readouts even when one vendor portfolio spans all three — matching how Gulf buyers fund decisions.',
        'Cross-link NUPCO tendering and GCC pharmacy hub content for internal navigation; SSR depth supports “GCC medication management market” and related zero-CTR queries from GSC.',
      ],
    },
  ],
};

const P0_TOPIC_LABEL: Record<string, string> = {
  'japan-medical-disposables-market': 'Japan hospital medical disposables',
  'japan-neurology-devices-market': 'Japan neurology devices',
  'singapore-ivd-market-access': 'Singapore IVD market access',
  'mek-inhibitors-market': 'MEK inhibitor market access',
  'febrile-neutropenia-market': 'febrile neutropenia and G-CSF',
  'italy-portable-diagnostic-devices-market': 'Italy portable diagnostics and POCT',
  'italy-medical-device-connectivity-market': 'Italy medical device connectivity',
  'gcc-medication-management-market': 'GCC medication management',
};

for (const [slug, label] of Object.entries(P0_TOPIC_LABEL)) {
  const sections = SPECIALTY_DEMAND_LONG_FORM[slug];
  if (!sections) continue;
  sections.push(
    {
      heading: `Scoping a BioNixus programme on ${label}`,
      paragraphs: [
        `Commercial and medical teams usually arrive on /${slug} with one dated decision — a tender, a protocol vote, a cluster lab validation, or a capital committee — rather than a generic “market sizing” ask. BioNixus starts with a forty-eight-hour feasibility pass: confirm the decision owner, the stakeholder mix, and whether qual depth, quant cuts, or message testing is appropriate for ${label}.`,
        `We document sample frames and recruitment risk before protocols lock so sponsors do not pay for field that cannot reach verified hospital, lab, or oncology stakeholders. Mixed-method designs are allowed, but each method must map to an explicit gate in the access or adoption path — otherwise readouts look impressive and still fail committee scrutiny.`,
        `Executive deliverables include a single-decision memo, objection themes with verbatim quotes suitable for MLR review, and a thirty/sixty/ninety-day action plan with evidence gaps flagged. Optional modules cover GCC pull-through, ASEAN sequencing, or RWE only when those gates are on the critical path for ${label}.`,
        `Minimum engagement sizes follow BioNixus healthcare norms (typically from USD 20,000 for scoped primary modules). Multinational roll-ups use harmonised instruments where valid, with country qual cells where procurement or regulatory context diverges.`,
        `Sponsors often pair this module with adjacent hub pages — country healthcare research, therapy hubs, or competitor-alternative briefs — so internal linking and field design stay coherent for medical affairs reviewers.`,
      ],
    },
    {
      heading: 'Quality, compliance, and AI-search-ready evidence',
      paragraphs: [
        `All ${label} fieldwork uses verified credentials, informed consent, de-identified reporting, and audit-ready methodology appendices. That discipline matters when medical affairs or access teams reuse quotes in payer decks or internal brand plans.`,
        `Pages like this one are maintained as server-rendered HTML with direct answer blocks, decision frameworks, and FAQ schema so Google and AI crawlers can cite practical definitions without executing client-side JavaScript — aligned with BioNixus sitewide SSR standards.`,
        `When content updates change committee context or tender language, dateModified in Service schema and sitemap lastmod should refresh on deploy so search systems and LLM indexes see current guidance.`,
      ],
    },
    {
      heading: 'Next steps for sponsors researching this topic',
      paragraphs: [
        `Use the healthcare market research hub to place ${label} in your wider launch or access plan, then request a scoped proposal with the decision date, target accounts, and countries on your charter.`,
        `BioNixus delivers from US, UK, Dubai, and Cairo offices with Arabic–English capability across the Gulf. Syndicated audits can inform sizing, but committee-ready decisions on ${label} require primary interviews with the stakeholders who hold veto power.`,
        `If your internal analytics team already tracks impressions on this topic in Search Console, align field modules to queries that show page-one positions with low CTR — often a title/meta fix is insufficient without deeper SSR evidence like the sections above.`,
        `Contact BioNixus via the research proposal form with your decision date, therapy or device class, and target countries — we respond with a scoped methodology and timeline, not a generic capabilities deck.`,
      ],
    },
    {
      heading: 'Deliverable formats and governance',
      paragraphs: [
        `Typical ${label} programmes deliver an executive deck, stakeholder-specific appendices, anonymised verbatim libraries, and a methodology note suitable for MLR or compliance review. Quant cuts include topline banners plus appendix tables; qual reports theme saturation criteria and document any deviating interviews.`,
        `Sponsors may reuse charts internally but should not treat this web page as the full dataset — it explains how BioNixus researches ${label}; commissioned work produces account-level evidence your teams own under contract.`,
      ],
    },
  );
}

export const SPECIALTY_DEMAND_EXTRA_FAQS: Record<string, Array<{ question: string; answer: string }>> = {
  'japan-medical-disposables-market': [
    {
      question: 'How long does Japan medical disposables market research take?',
      answer:
        'Feasibility and scoping often complete within two weeks; qual field for a single category typically runs three to five weeks depending on account access. Tender-aligned quant modules add time only when incidence and sample frames support the decision date.',
    },
    {
      question: 'Does BioNixus interview Japanese hospital nurses in Japanese?',
      answer:
        'Yes — Japanese-language moderation for nursing and infection-control depth is standard when sponsors need native nuance; global teams receive harmonised English readouts with quoted themes preserved for MLR.',
    },
    {
      question: 'What is the difference between syndicated data and BioNixus disposables research?',
      answer:
        'Syndicated audits describe what shipped; BioNixus primary research explains why wards and infection-control committees renew or reject SKUs after tender — the switching and workflow barriers that drive next-year share.',
    },
  ],
  'japan-neurology-devices-market': [
    {
      question: 'Can Japan neurology device research include proctors and distributors?',
      answer:
        'Yes — when training and service SLAs gate adoption, we include proctors and distributor technical specialists alongside physicians and hospital buyers so commercial plans reflect real bottlenecks.',
    },
    {
      question: 'How is Japan neurology device research different from general MedTech reports?',
      answer:
        'We isolate stroke-network protocols, NHI category economics, and neuro capital committees instead of blending neurology with orthopaedic or cardiac devices in one undifferentiated hospital survey.',
    },
    {
      question: 'Does BioNixus map Japanese stroke centre networks?',
      answer:
        'Yes — account maps show which designated centres set regional protocol templates so proctoring and KOL investment align with volume concentration.',
    },
  ],
  'singapore-ivd-market-access': [
    {
      question: 'How is Singapore IVD access different from HSA registration alone?',
      answer:
        'Registration is necessary; cluster lab validation, algorithm inclusion, and procurement convert registration into volume. BioNixus researches lab directors and pathologists who control those steps.',
    },
    {
      question: 'Which Singapore clusters does IVD access research cover?',
      answer:
        'Programs can scope SingHealth, NUHS, NHG, and selected private hospital labs — feasibility confirms access before protocols promise cluster-wide cuts.',
    },
    {
      question: 'How quickly can BioNixus start Singapore IVD access interviews?',
      answer:
        'After a forty-eight-hour scoping call, feasibility on lab-leader access typically completes within two weeks; qual field follows once protocols and recruit plans are approved.',
    },
  ],
  'mek-inhibitors-market': [
    {
      question: 'Does MEK inhibitor research include molecular pathology stakeholders?',
      answer:
        'Yes — pathology and testing pathway owners are core respondents because eligible pools depend on reflex rules, panel breadth, and turnaround time.',
    },
    {
      question: 'Can MEK access research run in parallel with GCC tender modules?',
      answer:
        'Yes — when Gulf listing is on the path we add pharmacy and tender stakeholders without conflating them with sequencing interviews in other markets.',
    },
    {
      question: 'What sample sizes apply to MEK message testing?',
      answer:
        'Message tests scale to the cuts you need for MLR — often thirty to fifty oncologists per cell — after qual documents the objections that must be tested.',
    },
  ],
  'febrile-neutropenia-market': [
    {
      question: 'Does febrile neutropenia research cover biosimilar G-CSF switching?',
      answer:
        'Yes — oncology pharmacist and oncologist interviews document substitution rules, confidence drivers, and protocol stickiness after tender or shortage events when sponsors need it.',
    },
    {
      question: 'Is febrile neutropenia research limited to prophylaxis?',
      answer:
        'No — we can scope inpatient FN treatment pathways and admission implications when brands message hospitalisation reduction, but we report prophylaxis, treatment, and tender economics separately in the readout deck for your team.',
    },
    {
      question: 'Which stakeholders are interviewed for G-CSF tender research?',
      answer:
        'Oncology pharmacists, medical oncologists, and procurement or tender owners — plus infectious-disease stakeholders when admission pathways are in scope. BioNixus verifies roles and institution type before interviews begin, and documents tender calendars when a dated award is the decision you are briefing.',
    },
  ],
  'italy-portable-diagnostic-devices-market': [
    {
      question: 'Does Italy portable diagnostics research cover regional ASL tenders?',
      answer:
        'Yes — regional procurement and lab governance vary; feasibility names the regions and hospital groups on your account list before field scales.',
    },
    {
      question: 'How does POCT research handle IVDR documentation expectations?',
      answer:
        'Lab director interviews capture validation workload and documentation barriers tied to IVDR — separate from clinical pathway pull modules.',
    },
    {
      question: 'Can portable diagnostics research include ED clinicians?',
      answer:
        'Yes — when acute turnaround is the use case, ED and ward leads are recruited alongside lab directors so pathway pull and lab governance are triangulated.',
    },
  ],
  'italy-medical-device-connectivity-market': [
    {
      question: 'Who are the primary buyers for connected devices in Italy?',
      answer:
        'Coalitions of CIO, cybersecurity, clinical engineering, and clinical department sponsors — BioNixus maps veto order before message testing.',
    },
    {
      question: 'Does connectivity research include tender language review?',
      answer:
        'Yes — we summarise interoperability and cybersecurity clauses that appear in regional MedTech RFPs and validate how evaluators weight them with buyer interviews.',
    },
    {
      question: 'How does BioNixus handle GDPR in connectivity interviews?',
      answer:
        'Interviews focus on hospital policy and risk acceptance — not patient data — with consent and de-identification suitable for vendor MLR and compliance review.',
    },
  ],
  'gcc-medication-management-market': [
    {
      question: 'Does GCC medication management research cover Wasfaty-linked workflows?',
      answer:
        'Yes — Saudi ambulatory and e-prescribing modules can include Wasfaty linkage when outpatient medication management is in scope.',
    },
    {
      question: 'Can automation and adherence be researched in one GCC programme?',
      answer:
        'They can run in parallel field, but readouts stay separated so pharmacy capex committees and payer adherence sponsors each get actionable evidence.',
    },
    {
      question: 'What is the minimum engagement for GCC medication management research?',
      answer:
        'Scoped primary modules typically start at USD 20,000 depending on countries, stakeholder mix, and qual depth — feasibility confirms recruitability before final quote.',
    },
  ],
};

